Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 2
2014 1
2021 1
2024 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study.
Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Dörks M, et al. Eur Child Adolesc Psychiatry. 2013 Aug;22(8):511-8. doi: 10.1007/s00787-013-0395-9. Epub 2013 Mar 3. Eur Child Adolesc Psychiatry. 2013. PMID: 23455627
In Germany, the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants (OADs) is not licensed for the treatment of depressive disorders in children and adolescents except for fluoxetine, which was approved in 2006. Against this background, antidep …
In Germany, the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants (OADs) is not licensed for the treatment of …
Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR, Theodore G. Maher AR, et al. J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. doi: 10.18553/jmcp.2012.18.s5-b.1. J Manag Care Pharm. 2012. PMID: 22784311 Free PMC article.
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripiprazole (as augmentation for major depressive disorder [MDD] and for autism spectrum disorders), asenapine, clozapine, iloperidone, olanzapine …
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripipr …
Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability.
Levy DM, Arush OB, Carmi L, Wetzler AJ, Zohar J. Levy DM, et al. Compr Psychiatry. 2024 Aug;133:152486. doi: 10.1016/j.comppsych.2024.152486. Epub 2024 Apr 15. Compr Psychiatry. 2024. PMID: 38703743 Free article.
Patients received sertraline >200 mg/day, escitalopram >20 mg/day, fluvoxamine >300 mg/day, and fluoxetine >60 mg/day, combined with exposure and response prevention therapy. Patients were divided into three dosing groups: sertraline equivalent dose (SED) 200 …
Patients received sertraline >200 mg/day, escitalopram >20 mg/day, fluvoxamine >300 mg/day, and fluoxetine >60 mg/day, co …
Pharmacotherapy in depressed children and adolescents.
Taurines R, Gerlach M, Warnke A, Thome J, Wewetzer C. Taurines R, et al. World J Biol Psychiatry. 2011 Sep;12 Suppl 1:11-5. doi: 10.3109/15622975.2011.600295. World J Biol Psychiatry. 2011. PMID: 21905988 Review.
As first-choice medication for the treatment of juvenile depression, the selective serotonin reuptake inhibitor (SSRI) fluoxetine is recommended, due to its efficacy and approval. As second-choice antidepressants the SSRIs sertraline, escitalopram and citalopram might be u …
As first-choice medication for the treatment of juvenile depression, the selective serotonin reuptake inhibitor (SSRI) fluoxetine is …
Pediatric Posttraumatic Stress Disorder Treatment Patterns: Insights from a Large Retrospective Study.
Baweja R, Padilla FM, Waschbusch DA, Waxmonsky JG. Baweja R, et al. J Clin Psychopharmacol. 2026 May-Jun 01;46(3):249-257. doi: 10.1097/JCP.0000000000002149. Epub 2026 Feb 9. J Clin Psychopharmacol. 2026. PMID: 42029666
Antidepressants were prescribed to 51.4% of patients, most commonly sertraline and fluoxetine. Antipsychotics were used in 30.5% of cases, but only 19.2% had prior psychotherapy. ...
Antidepressants were prescribed to 51.4% of patients, most commonly sertraline and fluoxetine. Antipsychotics were used in 30.5% of c …
An International Comparison of the Information in the Regulatory-Approved Drug Labeling and Prescribing Guidelines for Pediatric Depression.
Tanana L, Latif A, Nishtala PS, Taylor D, Chen TF. Tanana L, et al. J Child Adolesc Psychopharmacol. 2021 May;31(4):294-309. doi: 10.1089/cap.2020.0154. Epub 2021 Feb 18. J Child Adolesc Psychopharmacol. 2021. PMID: 33601936
Three of 30 drug labeling were consistent with MPGP recommendations (fluoxetine in the United Kingdom, fluoxetine and escitalopram in the United States). Differences in information between MPGP and the drug labeling were identified in 26 of 30 drug labeling analyzed …
Three of 30 drug labeling were consistent with MPGP recommendations (fluoxetine in the United Kingdom, fluoxetine and escitalo …
Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism.
Mouti A, Reddihough D, Marraffa C, Hazell P, Wray J, Lee K, Kohn M. Mouti A, et al. Trials. 2014 Jun 16;15:230. doi: 10.1186/1745-6215-15-230. Trials. 2014. PMID: 24934401 Free PMC article. Clinical Trial.
The efficacy and safety of SSRIs for moderating autistic behaviors is yet to be adequately examined to provide evidence to support current clinical practice. The aim of the Fluoxetine for Autistic Behaviors (FAB) study is to determine the efficacy and safety of low dose …
The efficacy and safety of SSRIs for moderating autistic behaviors is yet to be adequately examined to provide evidence to support current c …
[Depressive disorders in childhood and adolescence - an analysis of KinderAGATE 2010].
Stegmann B, Wenzel-Seifert K, Haen E. Stegmann B, et al. Z Kinder Jugendpsychiatr Psychother. 2013 Mar;41(2):109-19. doi: 10.1024/1422-4917/a000218. Z Kinder Jugendpsychiatr Psychother. 2013. PMID: 23425613 German.
In our sample male patients diagnosed with depression (58 % DPat, mean age 13.8 years) were treated more often and earlier than female patients (42 % DPat, mean age 15.3 years). Fluoxetine and mirtazapine were the most frequently prescribed substances. Sertraline, escitalo …
In our sample male patients diagnosed with depression (58 % DPat, mean age 13.8 years) were treated more often and earlier than female patie …